Thalassemia, a human blood disorder

Area of Science:

• Genetics
• Hematology
• Molecular Biology

Background:

• Thalassemia encompasses inherited blood disorders, primarily Alpha and Beta Thalassemia, resulting from gene mutations.
• These mutations cause reduced or malfunctioning alpha/beta globin proteins, essential for oxygen transport via heme attachment.
• Globin chain imbalances lead to hemolysis and impaired erythropoiesis, causing various clinical manifestations.

Purpose of the Study:

• To review the molecular basis of Thalassemia.
• To highlight the clinical spectrum and current treatment limitations.
• To emphasize the need for novel therapeutic strategies.

Main Methods:

• Literature review of Thalassemia genetics and molecular pathology.
• Analysis of clinical presentations from mild traits to severe forms.
• Examination of current therapeutic options and their limitations.

Main Results:

• Gene mutations on chromosomes 16 (alpha) and 11 (beta) disrupt globin protein synthesis.
• Clinical severity ranges from asymptomatic traits to severe conditions like hemolytic anemia, hydrops fetalis, and beta thalassemia major.
• Complications include iron overload from transfusions, leading to renal and hepatic impairment, classifying Thalassemia as a syndrome.

Conclusions:

• Current treatments like bone marrow transplant and gene therapy have limited success rates.
• A deeper understanding of Thalassemia's molecular underpinnings is crucial for developing permanent cures.
• Despite decades of research, Thalassemia remains a significant global health challenge requiring innovative treatment approaches.